share_log

西南证券4月16日发布研报称，给予国药一致（000028.SZ）买入评级。评级理由主要包括：1）四季度业绩短期承压，期间费率有所下降；2）分销业务稳步增长，零售业务盈利能力提升；3）国大药房加大门店拓展力度，积极创新线上下多渠道业务。（每日经济新闻）

Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates decline

Zhitong Finance ·  Apr 16 19:09
Southwest Securities released a research report on April 16 stating that Sinopharm was given a consistent (000028.SZ) purchase rating. The main reasons for the rating include: 1) the fourth quarter results were under short-term pressure, and rates declined during the period; 2) the distribution business grew steadily and the profitability of the retail business increased; 3) National University Pharmacy increased its store expansion efforts and actively innovated online and offline multi-channel businesses. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment